Xiang Lu
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma (NCT06235918) | Xiang Lu | 2023-01-01 |
Track Xiang Lu automatically
Every clearance here is in the API, with alerts when new ones post.